Commentary on: Combination of Metabolic Intervention and T Cell Therapy Enhances Solid Tumor Immunotherapy

Anthos Christofides; Natalia M Tijaro-Ovalle; Vassiliki A Boussiotis

doi:10.20900/immunometab20210016

Commentary on: Combination of Metabolic Intervention and T Cell Therapy Enhances Solid Tumor Immunotherapy

Immunometabolism. 2021;3(2):e210016. doi: 10.20900/immunometab20210016.

Authors

Anthos Christofides^{1

2

3}, Natalia M Tijaro-Ovalle⁴, Vassiliki A Boussiotis^{1

2

3}

Affiliations

¹ Division of Hematology-Oncology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
² Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
³ Cancer Center, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.
⁴ Yale School of Medicine, New Haven, CT 06510, USA.

Abstract

Metabolism is a common cellular feature. Cancer creates a suppressive microenvironment resulting in inactivation of antigen-specific T cells by metabolic reprogramming. Development of approaches that enhance and sustain physiologic properties of T cell metabolism to prevent T cell inactivation and promote effector function in the tumor microenvironment is an urgent need for improvement of cell-based cancer immunotherapies.

Keywords: CAR T cells; T cell activation; cancer immunotherapy; cholesterol.

Abstract

Grants and funding